Cancer and Autoimmunity: Autoimmune and Rheumatic Features in Patients with Malignancies

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2001 Apr 17

PMID 11302861

Citations 70

Authors

M Abu-Shakra

D Buskila

M Ehrenfeld

K Conrad

Y Shoenfeld

Affiliations

Soon will be listed here.

Abstract

Objectives: To review the autoimmune and rheumatic manifestations of patients with malignancy.

Methods: A Medline search of all published papers using keywords related to malignancies, autoimmunity, rheumatic diseases, and paraneoplastic syndromes.

Results: Patients with malignant diseases may develop autoimmune phenomena and rheumatic diseases as a result of (a) generation of autoantibodies against various autoantigens, including oncoproteins (P185, 1-myc, c-myc, c-myb), tumour suppression genes (P53), proliferation associated antigens (cyclin A, B1, D1, E; CENP-F; CDK, U3-RNP), onconeural antigens (Hu, Yo, Ri, Tr), cancer/testis antigens (MAGE, GAGE, BAGE, SSX, ESO, SCP, CT7), and rheumatic disease associated antigens (RNP, Sm). The clinical significance of the various autoantibodies is not clear. Anti-oncoprotein and anti-tumour suppression gene antigens are detected before the diagnosis of the cancer or in the early stages of the malignant disease, suggesting a potential diagnostic or prognostic role. Anti-onconeural antibodies are pathogenic and are associated with specific clinical neurological syndromes (anti-Hu syndrome and others). (b) Paraneoplastic syndromes, a wide range of clinical syndromes, including classic autoimmune rheumatic diseases that develop among patients with cancer. (c) Rheumatism after chemotherapy, a clinical entity characterised by the development of musculoskeletal symptoms after combination chemotherapy for malignancy.

Conclusion: Autoimmune and rheumatic features are not rare among patients with malignancies. They are the result of various diverse mechanisms and occasionally they may be associated with serious clinical entities.

Citing Articles

Long-term health outcomes by cancer diagnosed age among adolescent and young adult: multinational representative database.

Kim S, Shin D, Jeong S, Kang D, Cho J BMC Med. 2024; 22(1):260.

PMID: 38910233 PMC: 11194971. DOI: 10.1186/s12916-024-03488-8.

SLE: a cognitive step forward-a synthesis of rethinking theories, causality, and ignored DNA structures.

Rekvig O Front Immunol. 2024; 15:1393814.

PMID: 38895113 PMC: 11183320. DOI: 10.3389/fimmu.2024.1393814.

The greatest contribution to medical science is the transformation from studying symptoms to studying their causes-the unrelenting legacy of Robert Koch and Louis Pasteur-and a causality perspective to approach a definition of SLE.

Rekvig O Front Immunol. 2024; 15:1346619.

PMID: 38361929 PMC: 10867267. DOI: 10.3389/fimmu.2024.1346619.

Unraveling the complex interplay between anti-tumor immune response and autoimmunity mediated by B cells and autoantibodies in the era of anti-checkpoint monoclonal antibody therapies.

Soussan S, Pupier G, Cremer I, Joubert P, Sautes-Fridman C, Fridman W Front Immunol. 2024; 15:1343020.

PMID: 38318190 PMC: 10838986. DOI: 10.3389/fimmu.2024.1343020.

Gemcitabine-induced peripheral vascular disease and prolonged response in a patient with metastatic pancreatic adenocarcinoma: A case report.

Fabien M, Elodie P, Anna S, Addeo P, Meher B World J Clin Cases. 2023; 11(6):1372-1378.

PMID: 36926125 PMC: 10013109. DOI: 10.12998/wjcc.v11.i6.1372.

References

STOCKERT E, Jager E, Chen Y, Scanlan M, Gout I, Karbach J . A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med. 1998; 187(8):1349-54. PMC: 2212223. DOI: 10.1084/jem.187.8.1349. View

Sorokine I, Ben-Mahrez K, Bracone A, Thierry D, Ishii S, Imamoto F . Presence of circulating anti-c-myb oncogene product antibodies in human sera. Int J Cancer. 1991; 47(5):665-9. DOI: 10.1002/ijc.2910470506. View

Conrad K, Mehlhorn J . Diagnostic and prognostic relevance of autoantibodies in uranium miners. Int Arch Allergy Immunol. 2000; 123(1):77-91. DOI: 10.1159/000024426. View

Love P, Santoro S . Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med. 1990; 112(9):682-98. DOI: 10.7326/0003-4819-112-9-682. View

ONeill J, Murray N, Newsom-Davis J . The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain. 1988; 111 ( Pt 3):577-96. DOI: 10.1093/brain/111.3.577. View

Grisold W, Drlicek M . Paraneoplastic neuropathy. Curr Opin Neurol. 1999; 12(5):617-25. DOI: 10.1097/00019052-199910000-00016. View

Sigurgeirsson B, Lindelof B, Edhag O, Allander E . Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med. 1992; 326(6):363-7. DOI: 10.1056/NEJM199202063260602. View

Marusich M, Furneaux H, Henion P, Weston J . Hu neuronal proteins are expressed in proliferating neurogenic cells. J Neurobiol. 1994; 25(2):143-55. DOI: 10.1002/neu.480250206. View

Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J . Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci. 1997; 147(1):35-42. DOI: 10.1016/s0022-510x(96)05303-8. View

10.

Michl I, Zielinski C . More postchemotherapy rheumatism. J Clin Oncol. 1993; 11(10):2051-2. DOI: 10.1200/JCO.1993.11.10.2051. View

11.

Morris L, Lemak N, Arnett Jr F, Jordon R, Duvic M . Systemic lupus erythematosus diagnosed during interferon alfa therapy. South Med J. 1996; 89(8):810-4. DOI: 10.1097/00007611-199608000-00012. View

12.

Leibovitch L, George J, Levi Y, Bakimer R, Shoenfeld Y . Anti-actin antibodies in sera from patients with autoimmune liver diseases and patients with carcinomas by ELISA. Immunol Lett. 1995; 48(2):129-32. DOI: 10.1016/0165-2478(95)02456-5. View

13.

TRIVERS G, De Benedetti V, Cawley H, Caron G, Harrington A, BENNETT W . Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res. 1996; 2(10):1767-75. View

14.

Drlicek M, Bianchi G, Bogliun G, Casati B, Grisold W, Kolig C . Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a long-term survey of ovarian cancer patients. J Neurol. 1997; 244(2):85-9. DOI: 10.1007/s004150050054. View

15.

Paydas S, Sahin B, Zorludemir S . Sweet's syndrome accompanying leukaemia: seven cases and review of the literature. Leuk Res. 2000; 24(1):83-6. DOI: 10.1016/s0145-2126(99)00140-x. View

16.

Sanchez-Guerrero J, Gutierrez-Urena S, Vidaller A, Reyes E, Iglesias A, Alarcon-Segovia D . Vasculitis as a paraneoplastic syndrome. Report of 11 cases and review of the literature. J Rheumatol. 1990; 17(11):1458-62. View

17.

Humphrey G, Goodale M, Bowen C, Gati J, Vilis T, Rutt B . Differences in perceived shape from shading correlate with activity in early visual areas. Curr Biol. 1997; 7(2):144-7. DOI: 10.1016/s0960-9822(06)00058-3. View

18.

Matteson E, Hickey A, Maguire L, Tilson H, Urowitz M . Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. Rheumatoid Arthritis Azathioprine Registry Steering Committee. J Rheumatol. 1991; 18(6):809-14. View

19.

Creamer P, Lim K, George E, Dieppe P . Acute inflammatory polyarthritis in association with tamoxifen. Br J Rheumatol. 1994; 33(6):583-5. DOI: 10.1093/rheumatology/33.6.583. View

20.

Zuckerman E, Toubi E, Golan T, Sabo E, Shmuel Z, Yeshurun D . Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy. Br J Cancer. 1995; 72(2):447-51. PMC: 2034001. DOI: 10.1038/bjc.1995.353. View